Kevzara

Sarilumab, the active ingredient in Kevzara, is a IL-6 receptor antagonist presented as a 200 mg/1.5 mL prefilled syringe for subcutaneous use. It treats rheumatoid arthritis in adult patients who require disease‑modifying therapy. GNH USA supplies Kevzara as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Kevzara acts on the interleukin‑6 pathway to modify disease activity in rheumatoid arthritis. - Rheumatoid arthritis (moderate to severe): reduces joint pain, swelling and stiffness. - Rheumatoid arthritis with inadequate response to prior DMARDs: provides additional disease control. - Adult rheumatoid arthritis: improves physical function and slows radiographic progression.

Common Side Effects: - Injection site reactions: pain, erythema, or swelling at the injection site. - Neutropenia: reduced neutrophil count observed in laboratory tests. - Elevated liver enzymes: increases in ALT or AST levels. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Headache: mild to moderate intensity. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Serious infections: including bacterial, viral, or fungal infections requiring medical attention. - Gastrointestinal perforation: rare but potentially life‑threatening. - Hypersensitivity reactions: including anaphylaxis or severe skin reactions. - Cytopenias: significant reductions in blood cell lines beyond neutropenia. - Liver failure: severe hepatic injury with jaundice or coagulopathy. - Anaphylaxis: acute, systemic allergic response requiring emergency care.

Before initiating therapy, clinicians should evaluate patient risk factors and monitor laboratory parameters. - Screen for active infections: assess and treat before starting Kevzara. - Monitor complete blood count: watch for neutropenia and other cytopenias. - Assess liver function: check transaminases regularly during treatment. - Evaluate lipid profile: IL‑6 blockade may alter cholesterol levels. - Vaccination: administer required vaccines prior to therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Sarilumab may interact with other agents that affect immune function or drug metabolism. Major Interactions (Avoid): - Live vaccines: contraindicated during treatment. - Strong immunosuppressants (e.g., high‑dose corticosteroids): may increase infection risk. - Cytochrome P450 substrates: IL‑6 blockade can alter metabolism; monitor levels. Moderate Interactions (Monitor Closely): - Non‑live vaccines: may have reduced efficacy; assess response. - Anticoagulants: monitor INR as inflammatory changes can affect coagulation. - Concomitant DMARDs: adjust dosing based on clinical response and safety.